D. Boral Capital Reiterates “Buy” Rating for ImmunityBio (NASDAQ:IBRX)

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating restated by equities researchers at D. Boral Capital in a research report issued on Friday,Benzinga reports. They presently have a $30.00 target price on the stock.

Separately, EF Hutton Acquisition Co. I raised ImmunityBio to a “strong-buy” rating in a research report on Wednesday, October 23rd.

ImmunityBio Stock Performance

Shares of NASDAQ IBRX traded down $0.03 during trading on Friday, reaching $2.64. The stock had a trading volume of 666,546 shares, compared to its average volume of 5,036,437. The stock has a market cap of $1.84 billion, a PE ratio of -2.87 and a beta of 0.86. ImmunityBio has a one year low of $2.61 and a one year high of $10.53. The firm’s 50 day moving average price is $4.51 and its two-hundred day moving average price is $4.77.

Hedge Funds Weigh In On ImmunityBio

Several institutional investors have recently modified their holdings of IBRX. Captrust Financial Advisors bought a new position in shares of ImmunityBio during the third quarter valued at about $41,000. Virtu Financial LLC purchased a new stake in ImmunityBio in the third quarter worth about $51,000. Algert Global LLC purchased a new position in shares of ImmunityBio in the second quarter worth $86,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of ImmunityBio by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock valued at $99,000 after acquiring an additional 4,545 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new position in ImmunityBio during the second quarter worth approximately $105,000. 8.58% of the stock is owned by institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.